Timing of CSL's Change of CFO Queried by Bull -- Market Talk

Dow Jones
Oct 01

2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief Strategy Officer Ken Lim and there will be a supporting transition period. "In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026," analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20. (david.winning@wsj.com)

 

(END) Dow Jones Newswires

September 30, 2025 18:54 ET (22:54 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10